Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too.
The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010. Read more about the company’s history and its recent $40 million financing round hedge fund Viking Global Investors here. Viking’s investment was a note that will convert into the company’s common stock after the initial public offering at a discount—equal to 90 percent of the price per share of the… Read more »
UNDERWRITERS AND PARTNERS